An Open Label, Randomized, Single Dose, Crossover Study to Evaluate the Pharmacokinetics and Safety of DA-5213 10mg in Healthy Subjects
Latest Information Update: 16 Jun 2022
At a glance
- Drugs DA-5213 (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Dong-A ST
- 10 Jun 2022 Status changed from not yet recruiting to completed.
- 11 Nov 2021 New trial record